Easton Pharmaceuticals Inc. Announces Medical Marijuana Facility Buildout Nears Completion as per MMPR Health Canada Guidelin...
July 01 2014 - 8:00AM
Marketwired
Easton Pharmaceuticals Inc. Announces Medical Marijuana Facility
Buildout Nears Completion as per MMPR Health Canada Guidelines
Prior to Inspection Towards Obtaining MMJ Growers License
TORONTO, ON--(Marketwired - Jul 1, 2014) - Easton
Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company
provides status update on its medical marijuana initiative.
Easton Pharmaceuticals Inc. announces that as per updates it has
received, site facility build-out as mandated per health Canada
MMPR guidelines are near completion and soon ready for the
scheduling of a new inspection on MMJ property where Easton holds
exclusive option to purchase up to 50% ownership interest in
private MMPR medical marijuana grower located in Ontario,
Canada. The private MMJ Company has nearly completed the
process of finalizing all Health Canada site facility build-out
requirements and continues to remain confident that an inspection
by Health Canada will ultimately result in full approval of a
Medical Marijuana Growers License. It is believed that only a
lighting issue was the main impediment which needed to be
addressed. Currently, only 13 companies have received medical
marijuana growers' licensees under the new MMPR system that went
into effect on April 1st of this year. Health Canada has provided
conservative revenue guidance to the profitability of the new MMPR
system which can be viewed on its website. Easton has received many
inquiries for disclosure and details of the private company,
however the company at this point is unable to provide any names or
further information that would adversely affect the license which
has been the case with other US based companies in similar type
circumstances. No other updates including which town the facility
is located can be provided.
In other news, Easton has closed on an agreement on another
medical marijuana initiative and will shortly make a formal
announcement along with other updates on its other products and
business initiatives.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
involved in various pharmaceutical sectors that owns, designs,
develops, and markets topically-delivered drugs and therapeutic /
cosmetic healthcare products, focused on cancer and other health
issues related towards male and female sexual dysfunction, wound
healing, pain, motion sickness, scar and stretch marks, cellulite,
varicose veins and other conditions. The company is also
endeavoring to enter other potentially lucrative industries such as
medical marijuana. The company's gel formulation is thought to be
an innovative and unique transdermal delivery system. Easton
Pharmaceuticals' product "VIORRA" is an over-the-counter,
topical daily use product and aid for the treatment to restore and
improve vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder); the world market for these female
conditions is conservatively estimated to be in the billions.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
Safe Harbor This news release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (The "Act"). In particular, when used in the
preceding of discussion, the words "anticipate," "pleased," "plan,"
"confident that," "believe," "expect," "possible" or "intent to"
and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the
forward-looking statements. There are no guarantees or assurances
that any proposals, initiatives or negotiations will result in what
the company had originally intended. Any investment made into
Easton Pharmaceuticals would be classified as speculative and
risky. Such risks and uncertainties include, but are not limited
to, market conditions, general acceptance of the company's products
and technologies, competitive factors, the ability to successfully
complete additional or adequate financing, government approvals or
changes to proposed laws and other risks and uncertainties further
stated in the company's financial reports and filings.
Contact: Carla Pepe Easton Pharmaceuticals Inc. Tel: +1(416)
619-0291 Tel: +1(347) 284-0192 Email:
info@eastonpharmaceuticalsinc.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Aug 2023 to Aug 2024